Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays.
Carlsson, Anders LU ; Wingren, Christer LU ; Ingvarsson, Johan LU ; Ellmark, Peter LU ; Baldetorp, Bo LU ; Fernö, Mårten LU ; Olsson, Håkan LU
and Borrebaeck, Carl
LU
(2008)
In European Journal of Cancer
44(3).
p.472-480
- Abstract
- The driving force behind oncoproteomics is to identify biomarker signatures associated with a particular malignancy. Here, we have for the first time used large-scale recombinant scFv antibody microarrays in an attempt to classify metastatic breast cancer versus healthy controls, based on differential protein expression profiling of whole serum samples. Using this multiplexed and miniaturised assay set-up providing pM range sensitivities, breast cancer could be classified with a specificity and sensitivity of 85% based on 129 serum analytes. However, by adopting a condensed 11 analyte biomarker signature, composed of nine non-redundant serum proteins, we were able to distinguish cancer versus healthy serum proteomes with a 95% sensitivity... (More)
- The driving force behind oncoproteomics is to identify biomarker signatures associated with a particular malignancy. Here, we have for the first time used large-scale recombinant scFv antibody microarrays in an attempt to classify metastatic breast cancer versus healthy controls, based on differential protein expression profiling of whole serum samples. Using this multiplexed and miniaturised assay set-up providing pM range sensitivities, breast cancer could be classified with a specificity and sensitivity of 85% based on 129 serum analytes. However, by adopting a condensed 11 analyte biomarker signature, composed of nine non-redundant serum proteins, we were able to distinguish cancer versus healthy serum proteomes with a 95% sensitivity and specificity, respectively. When a subgroup of patients, not receiving anti-inflammatory drugs, was analysed, a novel eight analyte biomarker signature with a further improved predictive power was indicated. In a longer perspective, antibody microarray analysis could provide a tool for the development of improved diagnostics and intensified biomarker discovery for breast cancer patients. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1021672
- author
- Carlsson, Anders
LU
; Wingren, Christer
LU
; Ingvarsson, Johan
LU
; Ellmark, Peter
LU
; Baldetorp, Bo
LU
; Fernö, Mårten
LU
; Olsson, Håkan
LU
and Borrebaeck, Carl
LU
- organization
- publishing date
- 2008
- type
- Contribution to journal
- publication status
- published
- subject
- in
- European Journal of Cancer
- volume
- 44
- issue
- 3
- pages
- 472 - 480
- publisher
- Elsevier
- external identifiers
-
- pmid:18171612
- wos:000254027400024
- scopus:38749122786
- pmid:18171612
- ISSN
- 1879-0852
- DOI
- 10.1016/j.ejca.2007.11.025
- language
- English
- LU publication?
- yes
- id
- 93668718-b5d0-4e18-8811-7fc2c4f1bf6e (old id 1021672)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/18171612?dopt=Abstract
- date added to LUP
- 2016-04-01 12:36:24
- date last changed
- 2022-01-27 07:22:55
@article{93668718-b5d0-4e18-8811-7fc2c4f1bf6e,
abstract = {{The driving force behind oncoproteomics is to identify biomarker signatures associated with a particular malignancy. Here, we have for the first time used large-scale recombinant scFv antibody microarrays in an attempt to classify metastatic breast cancer versus healthy controls, based on differential protein expression profiling of whole serum samples. Using this multiplexed and miniaturised assay set-up providing pM range sensitivities, breast cancer could be classified with a specificity and sensitivity of 85% based on 129 serum analytes. However, by adopting a condensed 11 analyte biomarker signature, composed of nine non-redundant serum proteins, we were able to distinguish cancer versus healthy serum proteomes with a 95% sensitivity and specificity, respectively. When a subgroup of patients, not receiving anti-inflammatory drugs, was analysed, a novel eight analyte biomarker signature with a further improved predictive power was indicated. In a longer perspective, antibody microarray analysis could provide a tool for the development of improved diagnostics and intensified biomarker discovery for breast cancer patients.}},
author = {{Carlsson, Anders and Wingren, Christer and Ingvarsson, Johan and Ellmark, Peter and Baldetorp, Bo and Fernö, Mårten and Olsson, Håkan and Borrebaeck, Carl}},
issn = {{1879-0852}},
language = {{eng}},
number = {{3}},
pages = {{472--480}},
publisher = {{Elsevier}},
series = {{European Journal of Cancer}},
title = {{Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays.}},
url = {{http://dx.doi.org/10.1016/j.ejca.2007.11.025}},
doi = {{10.1016/j.ejca.2007.11.025}},
volume = {{44}},
year = {{2008}},
}